A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.

Trial Profile

A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Interleukin-7 (Primary) ; Interleukin-7 (Primary)
  • Indications Lymphopenia; Sepsis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms IRIS-7-B
  • Sponsors Revimmune LLC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top